Developed by an international consortium of 117 experts in legal, ethical, clinical, and AI domains—and featuring Champalimaud Foundation (CF) Principal Investigator Nikolas Papanikolaou—the framework provides a detailed roadmap for creating trustworthy medical AI, from the earliest design stages all the way through clinical deployment and monitoring.

It all began with a little theatre play.

Three women working in  neuroscience walk into the stage. They have to decide what will be the topic of the next Ar Event. After some discussion, they settle on the theatre. How does neuroscience explain what happens when people watch actors perform?, they want to know. So they put their white labcoats on to better think scientifically. 

Each year, the European Association for the Study of Obesity (EASO) and the Novo Nordisk Foundation, honours exceptional research contributions that enhance our understanding of obesity, its causes, complications, prevention, and management. 

Host

Christa Rhiner, Stem Cells and Regeneration Lab

Venue

Seminar room

The Champalimaud Foundation has always been at the intersection of cutting-edge science, and exceptional care. 

Specialising in cutting-edge cancer treatment, neuropsychiatry, and experimental clinical research, the Champalimaud Clinical Centre is committed to advancing personalised medicine through groundbreaking research, merging advanced technology with human-centred care.

Watch the video to see how the Champalimaud Foundation has been transforming healthcare and improving lives for the past 20 years—and how we’ll continue to do so in the future.